The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome
Access Status
Authors
Date
2009Type
Metadata
Show full item recordAbstract
RUNX3 is believed to have tumour suppressor properties in several cancer types. Inactivation of RUNX3 has been shown to occur by methylation-induced transcriptional silencing and by mislocalization of the protein to the cytoplasm. The aim of this study was to examine the clinical significance of RUNX3 expression in a large series of colorectal cancers using immunohistochemistry and tissue arrays. With advancing tumour stage, expression of RUNX3 in the nucleus decreased, whereas expression restricted to the cytoplasmic compartment increased. Nuclear RUNX3 expression was associated with significantly better patient survival compared to tumours in which the expression of RUNX3 was restricted to the cytoplasm (P=0.025). These results support a role for RUNX3 as a tumour suppressor in colorectal cancer. © 2009 Cancer Research UK.
Citation
Source Title
Collections
Related items
Showing items related by title, author, creator and subject.
-
Welch, Mathew D. (2011)Acute lymphoblastic leukaemia (ALL) is the most common cancer diagnosed in children aged 1-14 years. There have been vast improvements in clinical outcomes for children diagnosed with ALL with cure rates of up to 90% ...
-
Tan, M.; Choong, P.; Dass, Crispin (2010)The DNA enzyme Dz13, targeted against the oncogene c-Jun, is capable of inhibiting various model tumours in mice albeit in ectopic models of neoplasia. In previous studies using orthotopic models of disease, the inhibitory ...
-
Shah, S.; Roth, A.; Goya, R.; Oloumi, A.; Ha, G.; Zhao, Y.; Turashvili, G.; Ding, J.; Tse, K.; Haffari, G.; Bashashati, A.; Prentice, L.; Khattra, J.; Burleigh, A.; Yap, D.; Bernard, V.; McPherson, A.; Shumansky, K.; Crisan, A.; Giuliany, R.; Heravi-Moussavi, A.; Rosner, J.; Lai, D.; Birol, I.; Varhol, Richard; Tam, A.; Dhalla, N.; Zeng, T.; Ma, K.; Chan, S.; Griffith, M.; Moradian, A.; Cheng, S.; Morin, G.; Watson, P.; Gelmon, K.; Chia, S.; Chin, S.; Curtis, C.; Rueda, O.; Pharoah, P.; Damaraju, S.; MacKey, J.; Hoon, K.; Harkins, T.; Tadigotla, V.; Sigaroudinia, M.; Gascard, P.; Tlsty, T.; Costello, J.; Meyer, I.; Eaves, C.; Wasserman, W.; Jones, S.; Huntsman, D.; Hirst, M.; Caldas, C.; Marra, M.; Aparicio, S. (2012)Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers. Here we show in ...